Home/Pipeline/Next-Gen / Universal Flu Vaccines

Next-Gen / Universal Flu Vaccines

Influenza

Research / Early ClinicalActive

Key Facts

Indication

Influenza

Phase

Research / Early Clinical

Status

Active

Company

CSL Seqirus

About CSL Seqirus

CSL Seqirus is a mission-driven global leader in influenza vaccines, leveraging its position within the CSL Limited ecosystem to advance public health. Its strategy is built on a diversified technology platform, a broad product portfolio, and a robust global manufacturing footprint. The company plays a pivotal role in seasonal flu prevention and is a key partner to governments worldwide for pandemic response, underpinned by continuous R&D and strategic in-licensing.

View full company profile

Therapeutic Areas

Infectious Disease Pandemic Preparedness

Other Influenza Drugs

Drug	Company	Phase	Status
PanCytoVir™ (oral probenecid)	TrippBio	IND Submitted	Active
AI Programme - Influenza	Poolbeg Pharma	Discovery	Active - Target/Candidate ID
Influenza Antibodies	new/era/mabs	Research/Pre-clinical	Active
Influenza Countermeasure Program	DynPort Vaccines	Not Specified	Active
Influenza Vaccine	Medigen	Preclinical	Active
Nasal Influenza Vaccine	Abera Bioscience	Pre-clinical	Active
Zapnometinib (ATR-002)	Atriva Therapeutics	Phase 2	Active
EV25	Eradivir	Pre-clinical	Active
Not Specified	New Amsterdam Sciences	Pre-clinical	Active
Influenza Program	Arisan Therapeutics	Preclinical	Active
Universal Influenza Vaccine	Orlance	Pre-IND	Active
Enhanced Seasonal Influenza Vaccine	Orlance	Research	Active